Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 101, Issue 21, 2004, Pages 8186-8191

  Cryan, John F ^a,c   O'Leary, Olivia F ^a,b   Jin, Sung Ha ^a   Friedland, Julie C ^a   Ouyang, Ming ^a   Hirsch, Bradford R ^a   Page, Michelle E ^a,d   Dalvi, Ashutosh ^a   Thomas, Steven A ^a   Lucki, Irwin ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^c NOVARTIS PHARMA AG   (Switzerland)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DESIPRAMINE; DOPAMINE BETA MONOOXYGENASE; FLUOXETINE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; PARGYLINE; PAROXETINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THREO 3,4 DIHYDROXYPHENYLSERINE;

ADRENALIN RELEASE; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CONTROLLED STUDY; DBH GENE; DEPRESSION; DEVELOPMENTAL DISORDER; DISEASE SEVERITY; DNA MODIFICATION; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG SENSITIVITY; GENE; GENE DISRUPTION; GENE TARGETING; HIPPOCAMPUS; MOUSE; NEUROCHEMISTRY; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL;

ANIMALS; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSION; DESIPRAMINE; DOPAMINE BETA-HYDROXYLASE; DROXIDOPA; FLUOXETINE; GENE DELETION; MICE; MORPHOLINES; NOREPINEPHRINE; PAROXETINE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TAIL;

ANIMALIA;

EID: 2542602316     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.0401080101     Document Type: Article

References (48)

1. Frazer, A. (1997) J. Clin. Psychiatry 58, Suppl. 6, 9-25.
2. Stanford, S. C. (1996) Trends Pharmacol. Sci. 17, 150-154.
3. Owens, M. J., Knight, D. L. & Nemeroff, C. B. (2000) Biol. Psychiatry 47, 842-845.
4. Millan, M. J., Gobert, A., Lejeune, F., Newman-Tancredi, A., Rivet, J-M., Auclair, A. & Peglion, J-L. (2001) J. Pharmacol. Exp. Ther. 298, 565-580.
5. Nakayama, K. (2002) Naunyn-Schmiedeberg's Arch. Pharmacol. 365, 102-105.
6. Bymaster, F. P., Zhang, W., Carter, P. A., Shaw, J., Chernet, E., Phebus, L., Wong, D. T. & Perry, K. W. (2002) Psychopharmacology 160, 353-361.
7. Thomas, D. N., Nutt, D. J. & Holman, R. B. (1998) J. Psychopharmacol. 12, 366-370.
8. Hajos-Korcsok, E., McTavish, S. F. & Sharp, T. (2000) Eur. J. Pharmacol. 407, 101-107.
9. Beyer, C. E., Boikess, S., Luo, B. & Dawson, L. A. (2002) J. Psychopharmacol. 16, 297-304.
10. Abercrombie, E. D. & Zigmond, M. J. (1989) J. Neurosci. 9, 4062-4067.
11. Hughes, Z. A. & Stanford, S. C. (1996) Eur. J. Pharmacol. 317, 83-90.
12. Kostowski, W. (1985) Pol. J. Pharmacol. Pharm. 37, 727-743.
13. Redrobe, J. P., Bourin, M., Colombel, M. C. & Baker G. B. (1998) Psychopharmacology 138, 1-8.
14. Esposito, E., Ossowska, G. & Samanin, R. (1987) Eur. J. Pharmacol. 136, 429-432.
15. Cryan, J. F., Page M. E. & Lucki, I. (2002) Eur. J. Pharmacol. 436, 197-205.
16. Lucki, I. & O'Leary, O. F. (2004) J. Clin. Psychiatry 65, Suppl. 4, 11-24.
17. Thomas, S. A., Matsumoto, A. M. & Palmiter, R. D. (1995) Nature 374, 643-646.
18. Thomas, S. A. & Palmiter, R. D. (1997) Cell 91, 583-592.
19. Thomas, S. A. & Palmiter, R. D. (1997) Behav. Neurosci. 111, 579-589.
20. Cryan, J. F., Dalvi, A., Jin, S. H., Hirsch, B. R., Lucki, I. & Thomas, S. A. (2001) J. Pharmacol. Exp. Ther. 298, 651-657.
21. Weinshenker, D., Szot, P., Miller, N. S., Rust, N. C., Hohmann, J. G., Pyati, U., White, S. S. & Palmiter, R. D. (2001) J. Neurosci. 21, 7764-7769.
22. Thomas, S. A., Marck, B. T., Palmiter, R. D. & Matsumoto, A. M. (1998) J. Neurochem. 70, 2468-2476.
23. Steru, L., Chermat, R., Thierry, B. & Simon, P. (1985) Psychopharmacology 85, 367-370.
24. Cryan, J. F., Markou, A. & Lucki, I. (2002) Trends Pharmacol. Sci. 23, 238-245.
25. Cryan, J. F. & Mombereau, C. (2004) Mol. Psychiatry 9, 326-357.
26. Knobelman, D. A., Hen, R. & Lucki, I. (2001) J. Pharmacol. Exp. Ther. 298, 1083-1091.
27. Popik, P. (1999) J. Clin. Psychopharmacol. 19, 4S-22S.
28. Buck, K. J. & Amara, S. G. (1994) Proc. Natl. Acad. Sci. USA 91, 12584-12588.
29. Stanford, S. C. (1995) Pharmacol. Ther. 68, 297-342.
30. Valentino, R. J., Curtis, A. L., Page, M. E., Pavcovich, L. A. & Florin-Lechner, S. M. (1998) Adv. Pharmacol. 42, 781-784.
31. Page, M. E., Detke, M. J., Dalvi, A., Kirby, L. G. & Lucki, I. (1999) Psychopharmacology 147, 162-167.
32. Wong, E. H., Sonders, M. S., Amara, S. G., Tinholt, P. M., Piercey, M. F., Hoffmann, W. P., Hyslop, D. K., Franklin, S., Porsolt, R. D., Bonsignori, A., et al. (2000) Biol. Psychiatry 47, 818-829.
33. Weinshenker, D., White, S. S., Javors, M. A., Palmiter, R. D. & Szot, P. (2002) Brain Res. 946, 239-246.
34. Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., Golden, R. N., Martin, P., Potter, W. Z., Richelson, E. & Sulser, F. (1995) J. Clin. Psychiatry 56, 395-401.
35. Cooper, B. R., Wang, C. M., Cox, R. F., Norton, R., Shea, V. & Ferris, R. M. (1994) Neuropsychopharmacology 11, 133-141.
36. Dong, J. & Blier, P. (2001) Psychopharmacology 155, 52-57.
37. Reneric, J. P., Bouvard, M. & Stinus, L. (2002) Eur. Neuropsychopharmacol. 12, 159-171.
38. Cervo, L., Grignaschi, G., Rossi, C. & Samanin, R. (1991) Eur. J. Pharmacol. 196, 217-222.
39. Soubrie, P., Martin, P., el Mestikawy, S. & Hamon M. (1987) Brain Res. 437, 323-331.
40. Fuller, R. W., Hemrick-Luecke, S. K., Littlefield, E. S. & Audia J. E. (1995) Prog. Neuropsychopharmacol. Biol. Psychiatry 19, 135-149.
41. Sanchez, C. & Hyttel, J. (1999) Cell. Mol. Neurobiol. 19, 467-489.
42. Hughes, Z. A. & Stanford, S. C. (1998) Br. J. Pharmacol. 124, 1141-1148.
43. Baraban, J. M. & Aghajanian, G. K. (1980) Neuropharmacology 19, 355-363.
44. Bortolozzi, A. & Artigas, F. (2003) Neuropsychopharmacology 28, 421-434.
45. Delgado, P. L. (2000) J. Clin. Psychiatry 61, Suppl. 6, 7-11.
46. Healy, D. & McMonagle, T. (1997) J. Psychopharmacol. 11, S25-S31.
47. Blier, P. (2001) J. Psychiatry Neurosci. 26, S3-S10.
48. Gilbert, P. & Allan, S. (1998) Psychol. Med. 28, 585-598.